Treatment of chronic fatigue syndrome using selective agonists of toll-like re- ceptor 3 (TLR3)

Details for Australian Patent Application No. 2009302760 (hide)

Owner Hemispherx Biopharma, Inc.

Inventors Carter, William A.; Strayer, David

Agent Cullens

Pub. Number AU-A-2009302760

PCT Pub. Number WO2010/042229

Priority 61/136,889 10.10.08 US

Filing date 13 October 2009

Wipo publication date 15 April 2010

International Classifications

A61K 31/7105 (2006.01) - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links

A61P 43/00 (2006.01) Drugs for specific purposes, not provided for in groups

Event Publications

12 May 2011 PCT application entered the National Phase

  PCT publication WO2010/042229 Priority application(s): WO2010/042229

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2009302771-Limited-access, reduced-pressure systems and methods

2009302752-System and method for reducing a penalty period for a distributed power train